Could donor islet cells free diabetics from insulin after kidney transplant?

NCT ID NCT01241864

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether transplanting insulin-producing islet cells from deceased donors can help people with type 1 diabetes who have already received a kidney transplant. The goal is to achieve safe blood sugar levels without insulin shots. Ten participants will receive the cells via a vein in the liver and must take immunosuppressant drugs as long as the cells work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allogenic islet cells (donor pancreas cells) plus immunosuppressant drugs
What this could lead to: If successful, this could help people with type 1 diabetes who have had a kidney transplant achieve near-normal blood sugar without insulin shots, reducing complications.
What could go wrong: This is a very small early-phase trial (10 people) and requires lifelong immunosuppression, which carries risks like infection and organ damage. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

The University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.